The immunomodulatory ligand b7-1 mediates synaptic remodeling by p75ntr
AssigneeAlbert Einstein College of Medicine
InventorsBarbara Hempstead, Francis Lee, Roshelle Smith, Victor Danelon, Steven Almo, Nicholas Morano, Sarah Garrett
Life of this patent
Estimating the term…
Abstract
As described herein, binding of the B7-1 protein with the neuronal cell surface p75 neurotrophin receptor protein triggers loss of synaptic connections. Methods and compositions are also described for treatment of neurological diseases and conditions (including pain) and for identifying therapeutic agents useful for treatment of neurological diseases and conditions (including pain).
Claims18
A method comprising incubating one or more test agents with B7-1 and p75 neurotrophin receptor and measuring whether one or more of the test agents reduces B7-1 binding to p75 neurotrophin receptor.
A method comprising administering abatacept or belatacept to a subject having a neuronal condition or disease to thereby treat the neuronal condition or disease.
A method comprising administering a modified CTLA-4 protein that can block of B7 binding, a modified CD28 protein that can block of B7 binding, a modified Inducible T Cell Costimulator Ligand (ICOSL) protein that can block of B7 binding, or combinations thereof to a subject having a neuronal condition or disease to thereby treat the neuronal condition or disease.
18-37. (canceled)
Dependencies are inferred from the claim text.